Open Access1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced Pulmonary Fibrosis
Author(s) -
Robert G. Selker,
Samuel A. Jacobs,
Pearl Moore,
M D Niel Wald,
Edwin R. Fisher,
Manfred M.D. Cohen,
Peter Bellot
Publication year - 1980
Publication title -
neurosurgery/neurosurgery online
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.485
H-Index - 34
eISSN - 1081-1281
pISSN - 0148-396X
DOI - 10.1227/00006123-198012000-00003
Subject(s) - medicine , fibrosis , pulmonary fibrosis , pathology , nitrosourea , lung , carmustine , chemotherapy , cyclophosphamide
Clinical data are presented on 14 patients undergoing BCNU therapy for a primary intracranial glioma (11 biopsied, 3 suspected) in whom pulmonary fibrosis developed as a consequence of the therapy. Pulmonary diffusion abnormalities, dry hacking cough, and chest x-ray changes herald the onset of the process. Microscopic evaluation of lung specimens revealed a wide spectrum of change including hyaline membrane formation, alveolar septal thickening, interstitial fibrosis, and granuloma formation. It is concluded that BCNU causes pulmonary fibrosis that is primarily but not necessarily dose-related and may not be reversible.